Table 2.
PrEP randomized controlled trials and their findings
| Study (reference) | Location | Population | Efficacy | |
|---|---|---|---|---|
| Point estimate (%) | 95% CI | |||
| iPrEx (Grant et al. 2010) | Peru, Ecuador, Brazil, United States, South Africa, Thailand | MSM | 42 | 18 to 60% |
| Partners PrEP (Baeten et al. 2011) | Kenya, Uganda | Men | 84 | 49 to 94% |
| Women | 66 | 19 to 82% | ||
| TDF2 (Thigpen et al. 2012) | Botswana | Men | 80 | 25 to 97% |
| Women | 49 | 22 to 81% | ||
| FEM-PrEP (Van Damme et al. 2012) | Kenya, Tanzania | Women | 6 | −52 to 42% |
| VOICE (Marazzo et al. 2013) | South Africa, Uganda Zimbabwe |
Women | −4 | −50 to 30% |
| The CDC BTS (Choopaya et al. 2013) | Thailand | PWID | 49 | 10 to 72% |
| Ipergay (Molina et al. 2015) | France, Canada | MSM | 86 | 39 to 98% |
| PROUD (McCormack et al. 2015) | United Kingdom | MSM | 86 | 58 to 96% |